-
How would you interpret the 12-lead ECG shown in the Figure? What is distinctly unusual about this tracing? What would you ask the technician who recorded this tracing?
-
Sometimes, despite your best efforts, an accident occurs with new technology and a patient is injured or dies. Surprisingly, one of the most common mistakes that providers make is insufficient investigation or lack of response to an error so that it is repeated, says Bruce C. Hansel, PhD, executive director of forensic services at ECRI.
-
The Centers for Medicare & Medicaid Services has announced these rates for ambulatory surgery center groups, effective April 1, 2004.
-
-
When it comes to emergency contraception (EC), are you impeding access to women who might need it?
-
The most comprehensive analysis of U.S. HIV cases completed to date reveals that new HIV diagnoses in 29 states increased in 2002, according to the Centers for Disease Control and Prevention (CDC).
-
At the American College of Cardiology (Bethesda, Maryland) scientific sessions in early March at the Ernest N. Morial Convention Center, the sprawling exhibit floor was, as usual, a bustling center of activity. Perhaps no company embodied the spirit of constant on-the-go activity more than GE Healthcare (Waukesha, Wisconsin), the new umbrella moniker for all of General Electrics (Fairfield, Connecticut) healthcare-related companies.
-
Major progress has been made in the treatment of coronary heart disease in the UK, according to a report issued by Health Secretary John Reid. The report, Winning the War on Heart Disease, said that deaths from cardiovascular disease in the UK fell by more than 23% between the periods 1995-97 and 2000-02.
-
A story in the January issue of CDU included an incorrect reference to the InRatio point-of-care tester for prothrombin time as being an i-STAT (East Windsor, New Jersey) product. InRatio is manufactured by HemoSense (Milpitas, California).
-
In a move designed to shore up its sagging vascular brachytherapy (VBT) sales, which have been ravaged by the drug-eluting stent (DES) phenomenon, Novoste (Norcross, Georgia) said in an earnings conference call last month that it had signed an agreement with Guidant (Indianapolis, Indiana) to facilitate a transition to Novoste products by existing customers of Guidants vascular brachytherapy system in the U.S. and Canada.
